RxDoctor Payments Data

Paula Armstrong, NP

Nurse Practitioner · Stockbridge, GANPI 1467074203

Payments from drug & device makers

$1,154in general payments, 2019–2025

Across 52 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • Bayer$190
  • Daiichi Sankyo Inc.$190
  • Lilly USA, LLC$144
  • AstraZeneca$92
  • Boehringer Ingelheim$67
  • plus $246 from 9 others

What the payments were for

  • Food & beverage$1,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,154 in reported general payments places this provider in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$19,597
Medicare patients
111
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$56,250
JardianceEmpagliflozin15$18,556
MounjaroTirzepatide17$17,588
FarxigaDapagliflozin Propanediol11$14,543
Lidocaine13$1,119
Albuterol Sulfate HfaAlbuterol Sulfate41$1,087
Gabapentin50$698
Atorvastatin Calcium97$648
Pantoprazole Sodium36$539
Amlodipine Besylate111$451
Diclofenac Sodium19$441
Rosuvastatin Calcium19$384
Levothyroxine Sodium48$335
Memantine Hcl11$308
Olmesartan Medoxomil16$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$225$56,25050 claims
Boehringer IngelheimJardiance$67$18,55615 claims
Lilly USA, LLCMounjaro$144$17,58817 claims
AstraZenecaFarxiga$92$14,54311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →